Cost-effectiveness of endovascular treatment versus best medical management in basilar artery occlusion stroke: A U.S. healthcare perspective
European Stroke Journal · 2024
DOI: 10.1177/23969873231209616 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Stroke Journal, 2024. Verfasst von Dirk Mehrens und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Basilar Artery, Stroke. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Schlaganfall
Abstract (Originalsprache)
Introduction
Two recent studies showed clinical benefit for endovascular treatment (EVT) in basilar artery occlusion (BAO) stroke up to 12 h (ATTENTION) and between 6 and 24 h from onset (BAOCHE). Our aim was to investigate the cost-effectiveness of EVT from a U.S. healthcare perspective. Materials and Methods: Clinical input data were available for both trials, which were analyzed separately. A decision model was built consisting of a short-run model to analyze costs and functional outcomes within 90 days after the index stroke and a long-run Markov state transition model (cycle length of 12 months) to estimate expected lifetime costs and outcomes from a healthcare and a societal perspective. Incremental cost-effectiveness ratios (ICER) were calculated, deterministic (DSA) and probabilistic (PSA) sensitivity analyses were performed.
Results
EVT in addition to best medical management (BMM) resulted in additional lifetime costs of $32,063 in the ATTENTION trial and lifetime cost savings of $7690 in the BAOCHE trial (societal perspective). From a healthcare perspective, EVT led to incremental costs and effectiveness of $37,389 and 2.0 QALYs (ATTENTION) as well as $3516 and 1.9 QALYs (BAOCHE), compared to BMM alone. The ICER values were $−4052/QALY (BAOCHE) and $15,867/QALY (ATTENTION) from a societal perspective. In each trial, PSA showed EVT to be cost-effective in most calculations (99.9%) for a willingness-to-pay threshold of $100,000/QALY. Cost of EVT and age at stroke represented the greatest impact on the ICER.
Discussion
From an economic standpoint with a lifetime horizon, EVT in addition to BMM is estimated to be highly effective and cost-effective in BAO stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany.
- Institute of Neuroradiology, LMU University Hospital, LMU Munich, Munich, Germany.
- Department of Radiology, University of Tübingen, Tübingen, Germany.
- Departments of Radiology and Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.
- Department of Radiology, University Hospital of Basel, Basel, Switzerland.
- Department of Radiology and Nuclear Medicine, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany.
ORCID-Profile: Dirk Mehrens, Matthias P Fabritius, Johanna M Ospel, Julian Schwarting
Zitieren
APA
Mehrens, D., Fabritius, M. P., Reidler, P., Liebig, T., Afat, S., Ospel, J. M., Fröhlich, M. F., Schwarting, J., Ricke, J., Dimitriadis, K., Goyal, M., & Kunz, W. G. (2024). Cost-effectiveness of endovascular treatment versus best medical management in basilar artery occlusion stroke: A U.S. healthcare perspective. European Stroke Journal. https://doi.org/10.1177/23969873231209616
Vancouver
Mehrens D, Fabritius MP, Reidler P, Liebig T, Afat S, Ospel JM, et al. Cost-effectiveness of endovascular treatment versus best medical management in basilar artery occlusion stroke: A U.S. healthcare perspective. European Stroke Journal. 2024. doi:10.1177/23969873231209616
BibTeX
@article{Mehrens2024,
author = {Mehrens, Dirk and Fabritius, Matthias P and Reidler, Paul and Liebig, Thomas and Afat, Saif and Ospel, Johanna M and Fröhlich, Matthias F and Schwarting, Julian and Ricke, Jens and Dimitriadis, Konstantinos and Goyal, Mayank and Kunz, Wolfgang G},
title = {Cost-effectiveness of endovascular treatment versus best medical management in basilar artery occlusion stroke: A U.S. healthcare perspective},
journal = {European Stroke Journal},
year = {2024},
doi = {10.1177/23969873231209616}
}
EUVIMED